DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Bisoprolol (Bisoprolol Fumarate) - Summary

 
 



BISOPROLOL SUMMARY


Bisoprolol fumarate is a synthetic, beta1-selective (cardioselective) adrenoceptor blocking agent.


Bisoprolol fumarate tablets are indicated in the management of hypertension. They may be used alone or in combination with other antihypertensive agents.

See all Bisoprolol indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Bisoprolol

Hypertension, Related Mortality Rising Globally
Source: MedPage Today Endocrinology [2017.01.10]
(MedPage Today) -- Elevated SBP: the 'leading global contributor to preventable death'

Normal Blood Pressure in Clinic May Mask Hypertension
Source: MedicineNet Kidney Failure Specialty [2016.12.06]
Title: Normal Blood Pressure in Clinic May Mask Hypertension
Category: Health News
Created: 12/5/2016 12:00:00 AM
Last Editorial Review: 12/6/2016 12:00:00 AM

Hypertension and prehypertension underdiagnosed and undertreated in US children
Source: Hypertension News From Medical News Today [2016.11.24]
Hypertension and prehypertension in children often go undiagnosed, according to a new study published in Pediatrics.

Immune cells identified as the culprit linking hypertension and dementia
Source: Hypertension News From Medical News Today [2016.11.16]
Hypertension is a leading risk factor for dementia and other disorders associated with cognitive decline.

Offspring may have higher risk for developing hypertension if their parents had hypertension before age 55
Source: Hypertension News From Medical News Today [2016.11.14]
If your parents were diagnosed with high blood pressure before age 55, you may be at higher risk for developing high blood pressure than if they developed hypertension at a later age, according to...

more news >>

Published Studies Related to Bisoprolol

Influence of order and type of drug (bisoprolol vs. enalapril) on outcome and adverse events in patients with chronic heart failure: a post hoc analysis of the CIBIS-III trial. [2011.07]
CONCLUSION: The order of drug administration plays an important role in whether CHF patients reach target doses of bisoprolol and enalapril. For both study drugs, the dose level reached was associated with baseline characteristics and adverse events. In CHF patients not treated with an ACE-I or a beta-blocker, the duration of monotherapy with either type of drug should be shorter than 6 months.

Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. [2011.06]
CONCLUSION: Overall tolerability to target doses was comparable. The pattern of intolerance, however, was different: bradycardia occurred more often in the bisoprolol group, whereas pulmonary adverse events occurred more often in the carvedilol group. This study is registered with controlled-trials.com, number ISRCTN34827306.

Evaluation of the functional status questionnaire in heart failure: a sub-study of the second cardiac insufficiency bisoprolol survival study (CIBIS-II). [2011.02]
CONCLUSIONS: The FSQ performed well in this study, provided additional information to the MLwHF questionnaire and allowed interesting comparisons with other chronic medical conditions. The FSQ may be a useful general QoL instrument for studies in CHF.

Comparison of effectiveness of carvedilol versus bisoprolol for prevention of postdischarge atrial fibrillation after coronary artery bypass grafting in patients with heart failure. [2011.01.15]
Atrial fibrillation (AF) occurs frequently soon after coronary artery bypass grafting (CABG) and often results in increased mortality and morbidity, particularly in patients with heart failure. New-onset AF is also a common event in the early period after discharge from a cardiac surgery clinic... In conclusion, bisoprolol is more effective than carvedilol in decreasing the incidence of postdischarge AF after CABG in patients with decreased left ventricular function.

The effect of treatment with bisoprolol-first versus enalapril-first on cardiac structure and function in heart failure. [2010.09.24]
BACKGROUND: In CIBIS III, initiating chronic heart failure (CHF) treatment with bisoprolol (target dose 10 mg q.d.) followed by combination therapy with enalapril (target dose 10 mg b.i.d.), compared to the opposite order, showed similar effects on survival and hospitalization. By echocardiography, we evaluated the effects of these treatment strategies on cardiac structure and function... CONCLUSION: During both monotherapy and combined therapy, bisoprolol-first and enalapril-first similarly reversed cardiac remodelling and improved LVEF. Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.

more studies >>

Clinical Trials Related to Bisoprolol

Fixed Dose Combination of Bisoprolol and Amlodipine in the Treatment of Hypertension [Completed]

A Prospective, Open-labeled, Multi-centric Trial in Subjects With Systolic Heart Failure to Evaluate Bisoprolol Treatment for the Effects on Surrogate Markers of Heart Failure in Korea [Completed]
This is a prospective, open-labeled, multi-centric trial to evaluate the effect of bisoprolol (between low dose and high dose) on surrogate markers of heart failure in Korea.

Treating Clozapine-induced Sinustachycardia With Bisoprolol [Recruiting]
Clozapine-induced sinustachycardia occurs in 25% of patients treated with clozapine and sustained sinustachycardia might be a risk factor for dilated cardiomyopathy. This double-blinded cross over placebo controlled study investigate whether 10 mg bisoprolol are efficient in treating clozapine-induced sinustachycardia measured as heart rate, heart rate variability, QTc and T-wave morphology.

Phase 4 Study to Assess the Effect of Bisoprolol on Glycemic Level in Type II Diabetic Subjects With Suboptimal Blood Pressure Control [Completed]
This is a 24-week, prospective, multicenter, open-label, single-arm study to assess the effect of bisoprolol on glycemic level in Type 2 diabetes mellitus (T2DM) controlled subjects with hypertension. The hypothesis of study is that there is no change in glycemic level and lipid metabolism as determined by glycosylated hemoglobin (HbA1c) using bisoprolol in T2DM subjects with suboptimal blood pressure (BP) control.

Comparison of Bisoprolol With Metoprolol Succinate Sustained-release on Heart Rate and Blood Pressure in Hypertensive Patients [Completed]
This is a multicentre, randomized, open-label parallel trial to demonstrate the superiority and/or non-inferiority of bisoprolol on metoprolol succinate sustained-release (SR) tablet in subjects with mild to moderate primary hypertension.

more trials >>

Reports of Suspected Bisoprolol Side Effects

Dizziness (14)Nausea (12)Drug Hypersensitivity (11)Vertigo (11)Blood Pressure Increased (10)Hypoaesthesia (10)Visual Impairment (10)Hypotension (9)Vision Blurred (9)Renal Failure Acute (8)more >>


PATIENT REVIEWS / RATINGS / COMMENTS

Based on a total of 1 ratings/reviews, Bisoprolol has an overall score of 10. The effectiveness score is 10 and the side effect score is 10. The scores are on ten point scale: 10 - best, 1 - worst.
 

Bisoprolol review by 61 year old female patient

  Rating
Overall rating:  
Effectiveness:   Highly Effective
Side effects:   No Side Effects
  
Treatment Info
Condition / reason:   palpitations
Dosage & duration:   10mg taken daily for the period of 10 + years
Other conditions:   BP, cholesterol
Other drugs taken:   zocor
  
Reported Results
Benefits:   Immediately controled palpitations associated with mild to moderate mitral valve regurtitation
Side effects:   none
Comments:   one time daily

See all Bisoprolol reviews / ratings >>

Page last updated: 2017-01-10

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015